Liver transplantation is considered a safe procedure in selected HIV-positive patients with end-stage hepatic disease because of the advent of potent antiretroviral therapies.

Dolutegravir, a second-generation integrase inhibitor, may represent an attractive option for HIV-positive liver transplant recipients because of its minimal dependence on cytochrome P450 (CYP)-3A-mediated metabolism, high potency and high genetic barrier.

Our findings that 50% of patients from our database who had switched to dolutegravir returned to their previous regimens indicates the complexity of therapy management in HIV-positive liver transplant recipients in real-life settings.